FTSE 100 news / Companies and sectors / AstraZeneca / 1 October 2026
AstraZeneca (AZN): news on Thursday 1 October 2026
+7.0 strongly positive
Coverage centred on AstraZeneca's $2bn investment in Summit Therapeutics for cancer drug collaboration, which brokers praised and which saw the shares lead FTSE 100 healthcare higher. Pipeline news including an FDA filing, priority review for Imfinzi and a legal win over a Tagrisso rival added support, offset slightly by a loss in an Arkansas drug discount case.
What drove it
- Summit Therapeutics deal
- FDA filings and approvals
- Arkansas legal loss
The 20 stories
- +9.2 Brokers applaud AstraZeneca's $2bn Summit bet
Brokers positive on the Summit investment - +9.2 AstraZeneca (LSE:AZN) Wins FDA Priority Review For IMFINZI In Bladder Cancer
FDA priority review for Imfinzi in bladder cancer - +8.3 AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
$2bn investment and collaboration in cancer drugs, strategic pipeline expansion - +8.3 Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge
Legal challenge removed rival's EU approval, protecting Tagrisso - +7.5 AstraZeneca commits $2bn to advance ADC combination medicines for cancer
$2bn commitment to cancer combination medicines - +7.5 Why Did AstraZeneca (LSE:AZN) Lead FTSE 100 Healthcare Higher After Its Big Bet On Summit Therapeutics?
Led FTSE 100 healthcare higher after Summit deal - +7.5 AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes
FDA filing for lung cancer combination, pipeline progress - +7.5 700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3
Oral obesity pill advances to Phase 3 - −6.7 AstraZeneca Dealt Latest Loss in Arkansas Drug Discount Case
Another legal loss in drug discount case - +6.7 A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $191.8 to $267.19
Analyst forecasts show upside - +6.7 AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck
Big deal to compete with rivals in cancer - +5.8 SMMT climbs nearly 5% after AstraZeneca funds cancer drug development
Funding of cancer development, focus on Summit gain - +5.8 Summit Therapeutics Soars on AstraZeneca Mega Deal
Mega deal coverage, mainly Summit's gain - +5.0 AstraZeneca signs agreement with Cambridge University Health Partners on using real-world data for better healthcare
Data partnership agreement, modest positive - +5.0 Is AstraZeneca (LSE:AZN) Undervalued As Its Lung Cancer Filing Draws Fresh Attention?
Valuation piece citing lung cancer filing attention - +5.0 AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
Deal framed as vote of confidence - +5.0 Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing?
Valuation piece following new FDA filing - +5.0 AstraZeneca stock tracks a USD 2.0 billion cancer deal
Share price tracking the cancer deal - +2.5 AstraZeneca's Focus On Predictive Control, Semi-Autonomous Processing
Manufacturing approach feature, mildly positive - −1.7 AstraZeneca stock after-hours at EUR 143.58: minus 1.05 percent versus the prior close
Small after-hours share price dip
AstraZeneca: every day · Pharma and healthcare on 1 October 2026 · FTSE 100 overview for the day